EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|April 1, 2006
Progress continues in treating pediatric skin ailments
National report ? While topical calcineurin inhibitors for treating atopic dermatitis (AD) continue to grab headlines, sources tell Dermatology Times that research into additional treatments for pediatric skin problems is progressing.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
2
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
3
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
4
Alopecia Areata Awareness Month: 2026 in Review
5